Treatments for neuropathy

Abstract

Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions.

1 - 20 . (canceled) 
     
     
         21 . A method of treating or preventing a small fiber peripheral neuropathy in a subject determined to be in need thereof comprising: administering to the subject N 4 -{7-chloro-2-[(E)-2-(2-chloro-phenyl)-vinyl]-quinolin-4-yl}-N 1 ,N 1 -diethyl-pentane-1,4-diamine (XIB4035) or a pharmaceutically acceptable salt thereof under conditions effective to treat or prevent the peripheral neuropathy in the subject. 
     
     
         22 . The method of  claim 21 , wherein the XIB4035 is administered orally. 
     
     
         23 . The method of  claim 21 , wherein the XIB4035 is administered parenterally. 
     
     
         24 . The method of  claim 21 , wherein the XIB4035 is administered by injection. 
     
     
         25 . The method of  claim 21 , wherein the XIB4035 is administered by a route selected from the group consisting of subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by inhalation and by application to mucous membranes 
     
     
         26 . The method of  claim 21 , wherein the XIB4035 is applied to a mucous membrane selected from the group consisting of that of the nose, throat and bronchial tube. 
     
     
         27 . The method of  claim 21 , wherein the XIB4035 delivers systemically. 
     
     
         28 . The method of  claim 21 , wherein between 1 and 250 mg of XIB4035 is administered to the subject in a single dose. 
     
     
         29 . The method of  claim 21 , wherein the subject is human. 
     
     
         30 . The method of  claim 21 , further comprising the antecedent step of determining that the subject is in need of said method by detecting the small fiber neuropathy in the subject. 
     
     
         31 . The method of  claim 21 , further comprising the subsequent step of detecting a resultant diminution of the small fiber neuropathy. 
     
     
         32 . A formulation comprising N 4 -{7-chloro-2-[(E)-2-(2-chloro-phenyl)-vinyl]-quinolin-4-yl}-N 1 ,N 1 -diethyl-pentane-1,4-diamine (XIB4035) or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent a peripheral neuropathy in a subject, and a pharmaceutically acceptable carrier formulated for administration. 
     
     
         33 . The formulation of  claim 32 , wherein the formulation contains between about 1 to 250 mg of XIB4035. 
     
     
         34 . The formulation of  claim 32 , wherein the formulation comprises a dosage of XIB4035 effective for treatment of peripheral neuropathy in the subject. 
     
     
         35 . The formulation of  claim 32 , formulated for parenteral administration. 
     
     
         36 . The formulation of  claim 32 , formulated for injection. 
     
     
         37 . The formulation of  claim 32 , formulated for oral administration. 
     
     
         38 . The formulation of  claim 32 , formulated as a tablet. 
     
     
         39 . The formulation of  claim 32 , formulated for inhalation. 
     
     
         40 . The formulation of  claim 32 , wherein XIB4035 is present at about 2% to about 60% of the weight of the formulation.